China introduced a regulatory pathway known as “Order 818,” establishing an alternative approval track for certain advanced biomedical technologies designed to speed access for patients. The policy went into effect May 1 and allows specific advanced therapies—such as certain gene editing treatments, personalized cell therapies, and xenotransplantation—to pursue a parallel track rather than the traditional multi-phase drug approval approach. The reporting describes the goal as enabling earlier translation approval after meeting safety and preliminary efficacy thresholds, potentially reducing time to paid treatment for eligible innovations. It also flags expected knock-on effects for licensing negotiations between China-based innovators and global pharma. For biotech strategists, the track shifts regulatory timing risk and contract structures, particularly for companies deciding when to license out versus scale development domestically under faster review options.